Stephen J.LurieMD, PhD, Senior Editor
To the Editor: Halting the WHI estrogen plus progestin trial1 under its current stopping rules is entirely justified, but abandoning it altogether may not be. It is likely that many women, despite the increased chronic disease risks demonstrated in the trial, will wish to continue with long-term HRT for its benefit to their quality of life. It is therefore worthwhile considering what could be gained by extending the trial, and how its continuation might be achieved in an ethically acceptable manner.
Brunner E, Gillon R. Risks of Postmenopausal Hormone Replacement. JAMA. 2002;288(22):2821. doi:10.1001/jama.288.22.2821-JLT1211-1-8